EMAIL THIS PAGE TO A FRIEND

Immunology

Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis.


PMID 24467264

Abstract

Kallistatin, a plasma protein, has been shown to exert multi-factorial functions including inhibition of inflammation, oxidative stress and apoptosis in animal models and cultured cells. Kallistatin levels are reduced in patients with sepsis and in lipopolysaccharide (LPS)-induced septic mice. Moreover, transgenic mice expressing kallistatin are more resistant to LPS-induced mortality. Here, we investigated the effects of human kallistatin on organ injury and survival in a mouse model of polymicrobial sepsis. In this study, mice were injected intravenously with recombinant kallistatin (KS3, 3 mg/kg; or KS10, 10 mg/kg body weight) and then rendered septic by caecal ligation and puncture 30 min later. Kallistatin administration resulted in a > 10-fold reduction of peritoneal bacterial counts, and significantly decreased serum tumour necrosis factor-α, interleukin-6 and high mobility group box-1 (HMGB1) levels. Kallistatin also inhibited HMGB1 and toll-like receptor-4 gene expression in the lung and kidney. Administration of kallistatin attenuated renal damage and decreased blood urea nitrogen and serum creatinine levels, but increased endothelial nitric oxide synthase and nitric oxide levels in the kidney. In cultured endothelial cells, human kallistatin via its heparin-binding site inhibited HMGB1-induced nuclear factor-κB activation and inflammatory gene expression. Moreover, kallistatin significantly reduced apoptosis and caspase-3 activity in the spleen. Furthermore, kallistatin treatment markedly improved the survival of septic mice by 23% (KS3) and 41% (KS10). These results indicate that kallistatin is a unique protecting agent in sepsis-induced organ damage and mortality by inhibiting inflammation and apoptosis, as well as enhancing bacterial clearance in a mouse model of polymicrobial sepsis.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

AV38110
Anti-HMGB1 (AB2) antibody produced in rabbit, IgG fraction of antiserum
SAB2701685
Anti-hmgb1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701809
Anti-hmgb1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2101049
Anti-HMGB1 antibody produced in rabbit, affinity isolated antibody
SAB4501401
Anti-HMGB1 antibody produced in rabbit, affinity isolated antibody
N2643 Anti-Nitric Oxide Synthase, Endothelial (596-609) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB4300435
Anti-NOS3 (Ab-1177) antibody produced in rabbit, affinity isolated antibody
SAB4300491
Anti-NOS3 (Ab-495) antibody produced in rabbit, affinity isolated antibody
SAB1406188
Anti-NOS3 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
H4652 HMG-1 human, lyophilized powder, ≥90% (SDS-PAGE), Histidine-tagged, recombinant, expressed in E. coli
H9537
Monoclonal Anti-HMG-1 antibody produced in mouse, clone HAP46.5, purified from hybridoma cell culture
WH0003146M8
Monoclonal Anti-HMGB1 antibody produced in mouse, clone 2F6, purified immunoglobulin, buffered aqueous solution
SAB1403925
Monoclonal Anti-HMGB1 antibody produced in mouse, clone 1D5, purified immunoglobulin, buffered aqueous solution
N9532
Monoclonal Anti-Nitric Oxide Synthase, Endothelial antibody produced in mouse, clone NOS-E1, ascites fluid
SAB5300409 Monoclonal Anti-NOS3 antibody produced in mouse, clone 6H2, ascites fluid
SAB1402291
Monoclonal Anti-NOS3 antibody produced in mouse, clone 1D12, purified immunoglobulin, buffered aqueous solution